Skip to main content

Work Package 6

In Work Package 6, biomarker development and measurement will provide 4 key objectives:

  • Evaluation of biomarkers in an FDA approved lab under GLP/CLIA conditions enabling FDA submission and commercialisation.
  • Selection of biomarkers from Omics data, and development of simple in vitro diagnostic tools for worldwide use.
  • Validation of selected biomarkers in clinical trials compared to gold standard markers.
  • Selection of a biomarker, generating the FDA package as part of commercialisation efforts. This is crucial to provide a selected, developed and produced marker to laboratories worldwide.

Participating partners: 

Work Package Leader

Morten Asser Karsdal, Chief Executive Officer

Nordic Bioscience

Last Updated 06.09.2019